JCI Insight · 2018 · 67 citations · 31 references
MedicineImmunologyOncologyCancer ImmunologyDrug DeliveryImmunotherapyAntitumor T Cell ResponsesCancer ImmunotherapyCancer NanomedicineCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsTargeted Cancer TherapyAntigen Presenting CellsAntitumor Immune ActivationCancer Immunotherapy NanoparticlesCancer NanotherapyCheckpoint Inhibitor AntibodiesMonoclonal Antibodies In OncologyProgrammed Cell Death Protein 1 (Pd-1) PathwaySecondary Lymphoid Tissue
Recent studies in cancer research have focused intensely on the antineoplastic effects of immune checkpoint inhibitors. While the development of these inhibitors has progressed successfully, strategies to further improve their efficacy and reduce their toxicity are still needed. We hypothesized that the delivery of anti-PD-1 antibody encapsulated in PLGA nanoparticles (anti-PD-1 NPs) to the spleen would improve the antitumor effect of this agent. Unexpectedly, we found that mice treated with a high dose of anti-PD-1 NPs exhibited significantly higher mortality compared with those treated with free anti-PD-1 antibody, due to the overactivation of T cells. Administration of anti-PD-1 NPs to splenectomized LT-α-/- mice, which lack both lymph nodes and spleen, resulted in a complete reversal of this increased mortality and revealed the importance of secondary lymphoid tissues in mediating anti-PD-1-associated toxicity. Attenuation of the anti-PD-1 NPs dosage prevented toxicity and significantly improved its antitumor effect in the B16-F10 murine melanoma model. Furthermore, we found that anti-PD-1 NPs undergo internalization by DCs in the spleen, leading to their maturation and the subsequent activation of T cells. Our findings provide important clues that can lead to the development of strategies to enhance the efficacy of immune checkpoint inhibitors.
31
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +17
Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites
Filip K. Świrski, Matthias Nahrendorf, Martin Etzrodt et al. · Science · 2009 · 2.2K citations · Full text
Myocardial infarction accelerates atherosclerosis
Partha Dutta, Gabriel Courties, Ying Wei et al. · Nature · 2012 · 1.1K citations · Full text
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer, Yaron Carmi, Nathan E. Reticker-Flynn et al. · Cell · 2017 · 973 citations · Full text
Medicine, Immunology, Oncology +14